Given that cortex and striatum are the most vulnerable brain regions in HD, and are therefore the primary targets for therapeutic strategies aiming at reducing or eliminating Htt expression, we first assessed the impact of Htt loss in these two brain regions. The gene discussed is HTT; the disease is Huntington disease.